🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. REGN4336

    Regeneron UK Limited

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  2. REGN5093

    Lacuna Pharma Pty Ltd

    MET-altered non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  3. REGN5668

    Regeneron UK Limited

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  4. REGN5678

    Regeneron UK Limited

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  5. RELUGOLIX

    Fondazione Telethon ETS

    Intermediate risk prostate cancer

    phase 2 small molecule active

    1 trial

  6. RMC-4630

    Revolution Medicines

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  7. RMC-6236

    Revolution Medicines

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  8. RMC-6236

    Revolution Medicines

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  9. RMC-9805

    Revolution Medicines

    Lung Cancer

    phase 2 small molecule active

    1 trial

  10. RO7197597

    Hoffmann-La Roche

    Grade 1 Endometrial Cancer

    phase 2 small molecule active

    1 trial

  11. RO7790118, RO7791094, RO7790118, Tiragolumab, Avastin 25 mg/ml concentrate for solution for infusion., RO7247669, Tecentriq 1 200 mg concentrate for solution for infusion, RO7790118, TPST-1120, ADG126, RoActemra 20 mg/mL concentrate for solution for infusion

    Hoffmann-La Roche

    Advanced liver cancers

    phase 2 small molecule active

    1 trial

  12. RO7881583, EMPAGLIFLOZIN, Fulvestrant EVER Pharma 250 mg Injektionslösung in einer Fertigspritze, SACITUZUMAB GOVITECAN , Verzenios 100 mg film-coated tablets, EMPAGLIFLOZIN, PALBOCICLIB, INAVOLISIB, Tecentriq 1 200 mg concentrate for solution for infusion, LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, PALBOCICLIB, PALBOCICLIB, RoActemra 20 mg/mL concentrate for solution for infusion, Kisqali 200 mg film-coated tablets, Verzenios 50 mg film-coated tablets, Tecentriq, Abraxane 5 mg/ml powder for di

    Hoffmann-La Roche

    Metastatic breast cancer, including triple negative breast cancer (TNBC), hormone receptor positive breast cancer (HR+ BC), and HER2 positive and HER2 low breast cancer (HER2+/HER2-low BC)

    phase 2 small molecule active

    1 trial

  13. RX-3117

    Processa Pharmaceuticals

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  14. Radio-guided sentinel node biopsy

    Hospital Authority, Hong Kong

    Cancer of the Breast

    phase 2 other terminated

    1 trial

  15. Radiochemoimmunotherapy

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 other active

    1 trial

  16. Radiotherapy Combined with Anlotinib and a Microtubule Inhibitor

    The First People's Hospital of Lianyungang

    HER2-Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  17. Raltitrexed

    The First People's Hospital of Lianyungang

    Inoperable Esophageal Cancer Stage I-III

    phase 2 small molecule active

    1 trial

  18. Raludotatug Deruxtecan

    Daiichi Sankyo

    Advanced/metastatic solid tumors including gynecological cancers (endometrial cancer, cervical cancer, and nonhigh- grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and ccRCC)

    phase 2 small molecule active

    1 trial

  19. Raludotatug Deruxtecan (R-DXd)

    Merck KGaA, Darmstadt, Germany

    Gastrointestinal Cancer

    phase 2 mab active

    1 trial

  20. Recombinant Human Endostatin Injection

    The First People's Hospital of Lianyungang

    Locally Advanced Squamous Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  21. Recombinant human endostatin

    The First People's Hospital of Lianyungang

    Stage III Non-small-Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  22. Relacorilant

    CORCEPT THERAPEUTICS INC

    Recurrent Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  23. Relacorilant 150 mg once daily (QD)

    CORCEPT THERAPEUTICS INC

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  24. Relugolix

    Takeda

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources